In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors
about
Characterization of mutants of a tyrosine ammonia-lyase from Rhodotorula glutinis.Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.GD2-targeted immunotherapy and radioimmunotherapyChimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodyniaRetargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8Structural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody.Activation of human naïve Th cells increases surface expression of GD3 and induces neoexpression of GD2 that colocalize with TCR clusters.Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2.Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells.Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.Anti-GD2 immunotherapy for neuroblastoma.Therapeutic Antibodies to Ganglioside GD2 Evolved from Highly Selective Germline Antibodies.Emerging and investigational therapies for neuroblastoma.Engineering of a butyraldehyde dehydrogenase of Clostridium saccharoperbutylacetonicum to fit an engineered 1,4-butanediol pathway in Escherichia coli.
P2860
Q30390377-49C5D839-F6BA-4C4B-9B50-610E8A35E45CQ34389202-1F14EB29-8945-4E6F-9C7B-15D2816328BBQ34625339-BFCE5088-61C9-47A8-A4FD-3CCCD2C09EDBQ35092616-9B033D58-09EE-4120-8B8B-0AC27AE0E056Q35152029-B1BBA227-4F99-47B2-B7BC-186C90ED60DBQ35860917-9E3E6825-A56F-4A3C-91B6-77C373DEC423Q36133953-9E26E13F-D3C1-471C-8A37-BEC69543EF8AQ41492798-D99B0AC4-5423-4FB4-BDF3-403746B53698Q42079963-723AF231-A9C9-4A78-B6C6-35583F6AE48CQ42097486-85EE7989-E01D-4F36-8D7C-DFCD667E582AQ42153659-2B8B3B33-D180-466A-901F-E9FF0F649305Q47554435-01803DB5-77FE-4D3D-84C3-C0EDBC5D671DQ47945436-8BB6F044-6457-41E1-B0DF-BA8588CECF57Q50073387-4DDCBB99-1F62-473D-AB49-635C5A773D7FQ53635284-AC1D2AE0-75A5-4EC5-A269-6439503FD8AA
P2860
In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
In silico Driven Redesign of a ...... eatment of GD2 Positive Tumors
@ast
In silico Driven Redesign of a ...... eatment of GD2 Positive Tumors
@en
In silico Driven Redesign of a ...... eatment of GD2 Positive Tumors
@nl
type
label
In silico Driven Redesign of a ...... eatment of GD2 Positive Tumors
@ast
In silico Driven Redesign of a ...... eatment of GD2 Positive Tumors
@en
In silico Driven Redesign of a ...... eatment of GD2 Positive Tumors
@nl
prefLabel
In silico Driven Redesign of a ...... eatment of GD2 Positive Tumors
@ast
In silico Driven Redesign of a ...... eatment of GD2 Positive Tumors
@en
In silico Driven Redesign of a ...... eatment of GD2 Positive Tumors
@nl
P2093
P2860
P1433
P1476
In silico Driven Redesign of a ...... eatment of GD2 Positive Tumors
@en
P2093
Hong-Fen Guo
Mahiuddin Ahmed
Nai-Kong V Cheung
Yehuda Goldgur
P2860
P304
P356
10.1371/JOURNAL.PONE.0063359
P407
P577
2013-01-01T00:00:00Z